Cargando…

Mutation Analysis of Isocitrate Dehydrogenase (IDH1/2) and DNA Methyltransferase 3A (DNMT3A) in Thai Patients with Newly Diagnosed Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clonal hematopoietic stem/progenitor cell disorder which features several genetic mutations. Recurrent genetic alterations identified in AML are recognized as causes of the disease, finding application as diagnostic, prognostic and monitoring markers, with potential...

Descripción completa

Detalles Bibliográficos
Autores principales: Sirirat, Tanasan, Chuncharunee, Suporn, Nipaluk, Pimjai, Siriboonpiputtana, Teerapong, Chareonsirisuthigul, Takol, Limsuwannachot, Nittaya, Rerkamnuaychoke, Budsaba
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454736/
https://www.ncbi.nlm.nih.gov/pubmed/28345823
http://dx.doi.org/10.22034/APJCP.2017.18.2.413
_version_ 1783240891846098944
author Sirirat, Tanasan
Chuncharunee, Suporn
Nipaluk, Pimjai
Siriboonpiputtana, Teerapong
Chareonsirisuthigul, Takol
Limsuwannachot, Nittaya
Rerkamnuaychoke, Budsaba
author_facet Sirirat, Tanasan
Chuncharunee, Suporn
Nipaluk, Pimjai
Siriboonpiputtana, Teerapong
Chareonsirisuthigul, Takol
Limsuwannachot, Nittaya
Rerkamnuaychoke, Budsaba
author_sort Sirirat, Tanasan
collection PubMed
description Acute myeloid leukemia (AML) is a clonal hematopoietic stem/progenitor cell disorder which features several genetic mutations. Recurrent genetic alterations identified in AML are recognized as causes of the disease, finding application as diagnostic, prognostic and monitoring markers, with potential use as targets for cancer therapy. Here, we performed a pyrosequencing technique to investigate common mutations of IDH1, IDH2 and DNMT3A in 81 newly diagnosed AML patients. The prevalences of IDH1, IDH2 and DNMT3A mutations were 6.2%, 18.5%, and 7.4%, respectively. In addition, exclusive mutations in IDH1 codon 132 (R132H, R132C, R132G and R132S) were identified in all IDH1-mutated cases indicating that these are strongly associated with AML. Interestingly, higher median blast cell counts were significantly associated with IDH1/2 and DNMT3A mutations. In summary, we could establish a routine robust pyrosequencing method to detect common mutations in IDH1/2 and DNMT3A and demonstrate the frequency of those mutations in adult Thai AML patients.
format Online
Article
Text
id pubmed-5454736
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher West Asia Organization for Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-54547362017-08-28 Mutation Analysis of Isocitrate Dehydrogenase (IDH1/2) and DNA Methyltransferase 3A (DNMT3A) in Thai Patients with Newly Diagnosed Acute Myeloid Leukemia Sirirat, Tanasan Chuncharunee, Suporn Nipaluk, Pimjai Siriboonpiputtana, Teerapong Chareonsirisuthigul, Takol Limsuwannachot, Nittaya Rerkamnuaychoke, Budsaba Asian Pac J Cancer Prev Research Article Acute myeloid leukemia (AML) is a clonal hematopoietic stem/progenitor cell disorder which features several genetic mutations. Recurrent genetic alterations identified in AML are recognized as causes of the disease, finding application as diagnostic, prognostic and monitoring markers, with potential use as targets for cancer therapy. Here, we performed a pyrosequencing technique to investigate common mutations of IDH1, IDH2 and DNMT3A in 81 newly diagnosed AML patients. The prevalences of IDH1, IDH2 and DNMT3A mutations were 6.2%, 18.5%, and 7.4%, respectively. In addition, exclusive mutations in IDH1 codon 132 (R132H, R132C, R132G and R132S) were identified in all IDH1-mutated cases indicating that these are strongly associated with AML. Interestingly, higher median blast cell counts were significantly associated with IDH1/2 and DNMT3A mutations. In summary, we could establish a routine robust pyrosequencing method to detect common mutations in IDH1/2 and DNMT3A and demonstrate the frequency of those mutations in adult Thai AML patients. West Asia Organization for Cancer Prevention 2017 /pmc/articles/PMC5454736/ /pubmed/28345823 http://dx.doi.org/10.22034/APJCP.2017.18.2.413 Text en Copyright: © Asian Pacific Journal of Cancer Prevention http://creativecommons.org/licenses/BY-SA/4.0 This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
spellingShingle Research Article
Sirirat, Tanasan
Chuncharunee, Suporn
Nipaluk, Pimjai
Siriboonpiputtana, Teerapong
Chareonsirisuthigul, Takol
Limsuwannachot, Nittaya
Rerkamnuaychoke, Budsaba
Mutation Analysis of Isocitrate Dehydrogenase (IDH1/2) and DNA Methyltransferase 3A (DNMT3A) in Thai Patients with Newly Diagnosed Acute Myeloid Leukemia
title Mutation Analysis of Isocitrate Dehydrogenase (IDH1/2) and DNA Methyltransferase 3A (DNMT3A) in Thai Patients with Newly Diagnosed Acute Myeloid Leukemia
title_full Mutation Analysis of Isocitrate Dehydrogenase (IDH1/2) and DNA Methyltransferase 3A (DNMT3A) in Thai Patients with Newly Diagnosed Acute Myeloid Leukemia
title_fullStr Mutation Analysis of Isocitrate Dehydrogenase (IDH1/2) and DNA Methyltransferase 3A (DNMT3A) in Thai Patients with Newly Diagnosed Acute Myeloid Leukemia
title_full_unstemmed Mutation Analysis of Isocitrate Dehydrogenase (IDH1/2) and DNA Methyltransferase 3A (DNMT3A) in Thai Patients with Newly Diagnosed Acute Myeloid Leukemia
title_short Mutation Analysis of Isocitrate Dehydrogenase (IDH1/2) and DNA Methyltransferase 3A (DNMT3A) in Thai Patients with Newly Diagnosed Acute Myeloid Leukemia
title_sort mutation analysis of isocitrate dehydrogenase (idh1/2) and dna methyltransferase 3a (dnmt3a) in thai patients with newly diagnosed acute myeloid leukemia
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454736/
https://www.ncbi.nlm.nih.gov/pubmed/28345823
http://dx.doi.org/10.22034/APJCP.2017.18.2.413
work_keys_str_mv AT sirirattanasan mutationanalysisofisocitratedehydrogenaseidh12anddnamethyltransferase3adnmt3ainthaipatientswithnewlydiagnosedacutemyeloidleukemia
AT chuncharuneesuporn mutationanalysisofisocitratedehydrogenaseidh12anddnamethyltransferase3adnmt3ainthaipatientswithnewlydiagnosedacutemyeloidleukemia
AT nipalukpimjai mutationanalysisofisocitratedehydrogenaseidh12anddnamethyltransferase3adnmt3ainthaipatientswithnewlydiagnosedacutemyeloidleukemia
AT siriboonpiputtanateerapong mutationanalysisofisocitratedehydrogenaseidh12anddnamethyltransferase3adnmt3ainthaipatientswithnewlydiagnosedacutemyeloidleukemia
AT chareonsirisuthigultakol mutationanalysisofisocitratedehydrogenaseidh12anddnamethyltransferase3adnmt3ainthaipatientswithnewlydiagnosedacutemyeloidleukemia
AT limsuwannachotnittaya mutationanalysisofisocitratedehydrogenaseidh12anddnamethyltransferase3adnmt3ainthaipatientswithnewlydiagnosedacutemyeloidleukemia
AT rerkamnuaychokebudsaba mutationanalysisofisocitratedehydrogenaseidh12anddnamethyltransferase3adnmt3ainthaipatientswithnewlydiagnosedacutemyeloidleukemia